Evidence map›Paper›PMID 34069887›Full record

ReviewCancers2021

Radiomics in Differentiated Thyroid Cancer and Nodules: Explorations, Application, and Limitations.

Yuan Cao, Xiao Zhong, Wei Diao, Jingshi Mu, Yue Cheng, Zhiyun Jia

Abstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Radiomics in thyroid nodule assessment.BMC medical imaging · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuan CaoDepartment of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu 610040, China.ORCID 0000-0002-3105-7654
Xiao ZhongDepartment of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu 610040, China.
Wei DiaoDepartment of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu 610040, China.
Jingshi MuDepartment of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu 610040, China.ORCID 0000-0002-7867-7156
Yue ChengDepartment of Radiology, West China Hospital of Sichuan University, Chengdu 610040, China.
Zhiyun JiaDepartment of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu 610040, China.ORCID 0000-0003-1886-5654

Funding

1·3·5 Project for Disciplines of Excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University 2020HXFH005Innovation Spark Project of Sichuan University Grant No. 2019SCUH0003National Natural Science Foundation of China 81771812National Natural Science Foundation of China 81971595
6 · The paper itself

Abstract

Radiomics is an emerging technique that allows the quantitative extraction of high-throughput features from single or multiple medical images, which cannot be observed directly with the naked eye, and then applies to machine learning approaches to construct classification or prediction models. This method makes it possible to evaluate tumor status and to differentiate malignant from benign tumors or nodules in a more objective manner. To date, the classification and prediction value of radiomics in DTC patients have been inconsistent. Herein, we summarize the available literature on the classification and prediction performance of radiomics-based DTC in various imaging techniques. More specifically, we reviewed the recent literature to discuss the capacity of radiomics to predict lymph node (LN) metastasis, distant metastasis, tumor extrathyroidal extension, disease-free survival, and B-Raf proto-oncogene serine/threonine kinase (BRAF) mutation and differentiate malignant from benign nodules. This review discusses the application and limitations of the radiomics process, and explores its ability to improve clinical decision-making with the hope of emphasizing its utility for DTC patients.

Indexed as

classificationcomputer tomographydifferentiated thyroid cancermagnetic resonance imagingpredictionradiomicsultrasound

Identifiers

PMID34069887
PMCPMC8157383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.